Related Experiment Video
Updated: Feb 3, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
Published on: May 16, 2025
Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?
Konstantinos Tselios1,2, Mery Deeb1,2, Dafna D Gladman1,2
1From the University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network; University of Toronto, Krembil Research Institute; Department of Cardiology, University of Toronto, Women's College Hospital; Mecklinger Family and Posluns Family Cardiac Catheterization Research Laboratory, Department of Medicine, Division of Cardiology, Mount Sinai Hospital, University of Toronto; Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
Objective:
Antimalarials (AM) are recommended for all systemic lupus erythematosus (SLE) patients without specific contraindications. Their main adverse effect is retinal damage; however, heart disease has been described in isolated cases. The aim of our study is to describe 8 patients with AM-induced cardiomyopathy (AMIC) in a defined SLE cohort.
Methods:
Patients attending the Toronto Lupus Clinic and diagnosed with definite (based on endomyocardial biopsy; EMB) and possible AMIC were included [based on cardiac magnetic resonance imaging (cMRI) and other investigations].
Results:
Eight female patients (median age 62.5 yrs, disease duration 35 yrs, AM use duration 22 yrs) were diagnosed with AMIC in the past 2 years. Diagnosis was based on EMB in 3 (extensive cardiomyocyte vacuolation, intracytoplasmic myelinoid, and curvilinear bodies). In 4 patients, cMRI was highly suggestive of AMIC (ventricular hypertrophy and/or atrial enlargement and late gadolinium enhancement in a nonvascular pattern). Another patient was diagnosed with complete atrioventricular block, left ventricular and septal hypertrophy, along with concomitant ocular toxicity. All patients had abnormal cardiac troponin I (cTnI) and brain natriuretic peptide (BNP), whereas 7/8 also had chronically elevated creatine phosphokinase. During followup, 1 patient died from refractory heart failure. In the remaining patients, hypertrophy regression and a steady decrease of heart biomarkers were observed after AM cessation.
Conclusion:
Once considered extremely rare, AMIC seems to be underrecognized, probably because of the false attribution of heart failure or hypertrophy to other causes. Certain biomarkers (cTnI, BNP) and imaging findings may lead to early diagnosis and enhance survival.
Insights
Antimalarial-induced cardiomyopathy (AMIC) is underrecognized in systemic lupus erythematosus (SLE) patients. Early diagnosis using biomarkers and imaging can improve outcomes and survival.
Area of Science:
- Cardiology
- Rheumatology
- Toxicology
Background:
- Antimalarials (AM) are standard treatment for systemic lupus erythematosus (SLE).
- Retinal damage is a known AM adverse effect, but cardiac disease is rarely reported.
- This study describes 8 patients with AM-induced cardiomyopathy (AMIC) in an SLE cohort.
Observation:
- Eight female SLE patients (median age 62.5) were diagnosed with AMIC.
- Diagnosis involved endomyocardial biopsy (EMB) and cardiac magnetic resonance imaging (cMRI).
- Patients presented with cardiac hypertrophy, arrhythmias, and elevated cardiac biomarkers (cTnI, BNP, CK).
Findings:
- EMB showed cardiomyocyte vacuolation and myelinoid inclusions.
- cMRI revealed ventricular hypertrophy, atrial enlargement, and late gadolinium enhancement.
- One patient died from heart failure; others improved after AM cessation with biomarker normalization.
Implications:
- AMIC may be underdiagnosed, often misattributed to other causes.
- Biomarkers (cTnI, BNP) and cMRI are crucial for early AMIC diagnosis.
- Prompt diagnosis and AM cessation can enhance survival in SLE patients.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management

